India halts Sun Pharma eye-drug production over quality failures

The Directorate General of Pharmaceutical Administration (DGPA) issued the production halt directive after inspections revealed persistent quality control deficiencies at the manufacturing plant. The suspension affects output of the eye-care drug, a product category critical to both domestic and export markets across South and Southeast Asia.

Sun Pharmaceutical, which dominates India's pharmaceutical sector by market capitalisation, faces increased scrutiny from domestic regulators in recent months. The company has not publicly disclosed the specific nature of the quality lapses or the timeline for remediation required before operations can resume.

The regulatory action underscores growing concerns among Indian health authorities regarding manufacturing standards at major pharmaceutical facilities. The country supplies significant volumes of generic medications throughout the region, making quality compliance increasingly important for regulators and international trading partners.

Sun Pharma operates multiple manufacturing sites across India and internationally. The company is expected to implement corrective measures at the affected facility to address the quality deficiencies and seek clearance from regulators before resuming production of the eye-care medication.